Sci Tech Daily A new experimental vaccine takes aim at one of tuberculosis’s most stubborn defenses: the ability of bacteria to persist despite treatment.
In a study published in the Journal of Clinical Investigation, researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report developing a therapeutic DNA vaccine delivered through the nose for tuberculosis (TB). The vaccine combines two genes designed to train the immune system to target drug-tolerant bacterial “persisters,” which can survive long courses of antibiotics and lead to disease relapse.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.